Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 placebo-controlled trial of MAP-targeted therapeutic vaccines in Crohn's disease
ISRCTN13731766Phase 2Not yet recruiting
- Sponsor
- HAV Vaccines Limited
- Start
- Sep 2027
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
01
Overview
Phase 2, randomised trial of ChAdOx2 HAV in Crohn's disease (2 arms), sponsored by HAV Vaccines Limited. Primary endpoint: Clinical remission at Day 112. Planned start Sep 2027; status: not yet recruiting.
02
Drugs
ChAdOx2 HAV
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on ISRCTN13731766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN13731766.